"Skinny Labels" for Generic Drugs Under Hatch-Waxman Topic of White Paper From CRS
January 29, 2026
January 29, 2026
WASHINGTON, Jan. 29 (TNSLrpt) -- The Congressional Research Service issued the following In Focus white paper (No. IF12700) on Jan. 28, 2026, by legislative attorney Kevin J. Hickey:
* * *
"Skinny Labels" for Generic Drugs Under Hatch-Waxman
New "brand-name" drugs are often protected from generic competition by patents. In general, a drug manufacturer intending to market a generic version of a brand-name drug must either wait for those p . . .
* * *
"Skinny Labels" for Generic Drugs Under Hatch-Waxman
New "brand-name" drugs are often protected from generic competition by patents. In general, a drug manufacturer intending to market a generic version of a brand-name drug must either wait for those p . . .